SHIELD THERAPEUTICS PLC — Board/Management Information 2016

Nov 7, 2016

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 4406O

Shield Therapeutics PLC

07 November 2016

Shield Therapeutics plc

("Shield" or the "Group")

Board change

London, UK, 7 November 2016.  Shield Therapeutics plc (LSE:STX), a specialty pharmaceutical company focused on secondary care, announces that Richard Jones, Chief Financial Officer, will leave the Group in early 2017 to pursue a new opportunity.  Until his departure Richard will continue as a Board member and Shield's Chief Financial Officer, with a focus on progressing key commercialisation workstreams as well as facilitating an orderly transition.  A further announcement regarding the appointment of a new Chief Financial Officer will be made in due course.

Carl Sterritt, Chief Executive Officer of Shield Therapeutics, said: "Richard has helped build the Group from its inception as a small private company through to being listed on AIM.  I would like to thank him for his significant contribution to Shield and wish him the best in his future endeavours as we continue to grow rapidly into a commercial-stage specialty pharmaceutical business with international operations."

Richard Jones added: "I have thoroughly enjoyed my six and a half years of service to Shield, working with Carl and the team, and I am very proud of what we have achieved.  It is now time to apply my skills to a new challenge."

- Ends -

For further information please contact:

Shield Therapeutics plc	+44 (0)207 186 8500
Carl Sterritt, Chief Executive Officer
Nominated Adviser and Broker Liberum Capital Limited Christopher Britton/Steve Pearce	+44 (0)20 3100 2222
Financial PR Advisor Consilium Strategic Communications	+44 (0)203 709 5700 shieldtherapeutics@consilium-comms.com
Mary-Jane Elliott/Matthew Neal

About Shield Therapeutics plc

Shield Therapeutics is a specialty pharmaceutical company focused on the commercialisation and development of late-stage, hospital-focused pharmaceuticals which address areas of unmet medical need. The Group has a marketed product, Feraccru®, for the treatment of iron deficiency anaemia (IDA) which has exclusive IP rights until 2034. In addition, the Group is developing PT20, a late-stage pharmaceutical for the treatment of systemic phosphate accumulation (hyperphosphatemia). Shield Therapeutics, headquartered in London, is listed on LSE's AIM under the ticker STX. For more information please visit www.shieldtx.com. 

This information is provided by RNS

The company news service from the London Stock Exchange

END

BOAUNSURNNAARUA